We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

580 hedge funds and large institutions have $18.9B invested in BioMarin Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 88 funds opening new positions, 199 increasing their positions, 205 reducing their positions, and 48 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more first-time investments, than exits

New positions opened: 88 | Existing positions closed: 48

58% more call options, than puts

Call options by funds: $185M | Put options by funds: $117M

21% more capital invested

Capital invested by funds: $15.6B → $18.9B (+$3.24B)

15% more funds holding in top 10

Funds holding in top 10: 13 → 15 (+2)

5% more funds holding

Funds holding: 551 → 580 (+29)

3% less repeat investments, than reductions

Existing positions increased: 199 | Existing positions reduced: 205

2.06% less ownership

Funds ownership: 100.47% → 98.41% (-2.1%)

Holders
580
Holders Change
+29
Holders Change %
+5.26%
% of All Funds
9.32%
Holding in Top 10
15
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+15.38%
% of All Funds
0.24%
New
88
Increased
199
Reduced
205
Closed
48
Calls
$185M
Puts
$117M
Net Calls
+$68.2M
Net Calls Change
+$35.2M

Top Buyers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
+$134M
2
CG
Carmignac Gestion
France
+$81.5M
3
Capital Research Global Investors
Capital Research Global Investors
California
+$67.1M
4
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$66.7M
5
Bank of New York Mellon
Bank of New York Mellon
New York
+$52.4M

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$410M
2
Millennium Management
Millennium Management
New York
-$102M
3
Ameriprise
Ameriprise
Minnesota
-$98.3M
4
Citadel Advisors
Citadel Advisors
Florida
-$81.8M
5
PHS
PFM Health Sciences
California
-$75.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
MPCL
576
My Personal CFO LLC
Washington
$414 +$376 +4 New
TWD
577
True Wealth Design
Ohio
$414 +$376 +4 New
WIM
578
Westside Investment Management
California
$228 -$15K -160 -7%
HNB
579
Huntington National Bank
Ohio
$103 -$1.03K -11 -92%
CCM
580
Camber Capital Management
Massachusetts
– -$67.8M -800,000 Closed
WP
581
Woodline Partners
California
– -$17.4M -204,693 Closed
Nomura Holdings
582
Nomura Holdings
Japan
– -$17M -200,653 Closed
MAM
583
Melqart Asset Management
United Kingdom
– -$13.2M -155,849 Closed
SH
584
SeaTown Holdings
Singapore
– -$10.4M -122,175 Closed
TA
585
Tamarack Advisers
California
– -$6.02M -71,000 Closed
PHP
586
Parkman Healthcare Partners
Connecticut
– -$3.64M -42,961 Closed
GCM
587
Graham Capital Management
Connecticut
– -$2.63M -31,003 Closed
QT
588
Quantbot Technologies
New York
– -$1.83M -21,612 Closed
ACM
589
Aquatic Capital Management
Illinois
– -$1.83M -21,600 Closed
APP
590
Alpha Paradigm Partners
Illinois
– -$1.51M -17,850 Closed
ACM
591
AlphaCrest Capital Management
New York
– -$1.38M -16,264 Closed
Walleye Trading
592
Walleye Trading
New York
– -$1.14M -12,174 Closed
VF
593
Virtu Financial
New York
– -$896K -10,575 Closed
ESCM
594
Echo Street Capital Management
New York
– -$825K -9,729 Closed
MA
595
MUFG Americas
New York
– -$805K -9,486 Closed
Wolverine Trading
596
Wolverine Trading
Illinois
– -$867K -9,237 Closed
Simplex Trading
597
Simplex Trading
Illinois
– -$828K -8,825 Closed
KF
598
Krilogy Financial
Missouri
– -$681K -8,035 Closed
AAM
599
Azzad Asset Management
Virginia
– -$868K -7,035 Closed
WHG
600
Westwood Holdings Group
Texas
– -$586K -6,904 Closed
21 22 23
24
25

BMRN Hedge Fund Activity: Q4 2022 in Review

580 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2022, worth a combined $18.9B — up 21% from $15.6B a quarter earlier.

Buyers outnumbered sellers: 88 funds opened new BMRN positions and 48 closed out — a net gain of 40 holders — while 199 added to existing stakes and 205 trimmed.

The largest buyer was Invesco, adding an estimated $134M. The largest seller was Janus Henderson Group, cutting an estimated $410M.

  • 580 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2022, up from 551 in Q3 2022.
  • Funds reported $18.9B of BioMarin Pharmaceuticals stock for Q4 2022, up 21% quarter-over-quarter.
  • 88 funds opened new BioMarin Pharmaceuticals positions in Q4 2022 and 48 closed out, a net change of +40 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q4 2022 was Invesco, an estimated $134M added.
  • The largest BioMarin Pharmaceuticals seller in Q4 2022 was Janus Henderson Group, an estimated $410M sold.

Based on aggregated 13F filings for Q4 2022.